Medical treatment with various cytokines can provoke psychiatric symptoms. Conversely, psychiatric patients can display abnormalities in cytokine and neurotrophic factor expression. Such observations have pointed to the potential contribution of cytokines and growth factors to schizophrenic pathology and/or etiology. The cellular targets of the relevant factors and the nature of their actions remain to be explored in mental illness, however. Recent physiological studies demonstrate that cytokines and neurotrophic factors can markedly influence synaptic transmission and plasticity upon acute or chronic application. Moreover, many of the molecular alterations observed in the schizophrenic brain are consistent with abnormalities in cytokine and neurotrophic factor regulation of these molecules. In this review, we summarize these molecular pathology findings for schizophrenia and highlight the neurodevelopmental activities of cytokines and neurotrophic factors that may contribute to the etiology or pathology of this illness. Molecular Psychiatry (2000) 5, 594-603.
Introduction
The average lifetime prevalence of schizophrenia is estimated to be 0.5-1% worldwide, making the social costs of this disease extraordinarily high. It is therefore critical to mount an enormous effort to better understand the causes of this disease, and to provide better therapeutic options. However, given that this is a psychiatric syndrome with multiple diagnoses, and that it is a disorder of cognitive function, is it a feasible goal to understand schizophrenia at a molecular level? Will it be possible to develop reliable molecular markers for this disease, and to make animal models? Such efforts will be aided by the fact that there is a strong genetic component to this disease. 1 Finding the genes that predispose to schizophrenia should provide an important breakthrough. Perhaps equally important are findings that genetics is only part of the story. For instance, the incidence of schizophrenia when one identical twin has the disease is only 50% in the other twin. 2 The latest large epidemiological study in Denmark has emphasized the effect of season-of-birth as well as that of place of birth. 3 A number of other environmental factors have been implicated in schizophrenia, including birth trauma, 4 maternal viral infection, 5 nutritional
Correspondence: H Nawa, Department of Molecular Neurobiology, Brain Research Institute, Niigata University, 1-757 Asahimachi-dori, Niigata 951-8585, Japan Received 31 August 1999; revised 22 September 1999 and 10 January 2000; accepted 10 January 2000 deficiency, 6 and season of birth. 7 Moreover, some neuropathological findings have suggested that this disease arises from defective embryological development in selective brain areas. 8, 9 Relatively subtle changes in migration and/or differentiation of neural progenitor cells may produce brain atrophy, reduction of interneurons, and brain malformation. 10 Such defects are likely to have occurred during embryonic development and presumably result in impaired neural networks and function in the mature brain. 11 Although some of the findings are controversial, we argue that alterations in the levels of a number of preand post-synaptic proteins observed in schizophrenic brains could be due to disrupted growth factor or cytokine regulation of these molecules during development. In addition, analysis of cerebral spinal fluid and serum has revealed altered levels of certain cytokines in adult schizophrenic patients. Such changes are also consistent with altered immune function in this disease. 12 Indeed, there is a bi-directional communication between the brain and the immune system, such that alterations in one can lead to profound changes in the other, during development as well as in maturity. 13, 14 In this review, we first summarize relevant pathological and molecular findings for schizophrenia and correlate them with abnormalities found in the neurotrophic factor/cytokine systems thus far. We draw attention to the roles of growth factors and cytokines in regulating brain development, and particularly the control of those proteins that are known to be altered in schizophrenia.
Neuropathology
One of the distinctive features of the pathology in some schizophrenic patients is neuronal disorientation and brain atrophy without gliosis, which suggests the absence of ongoing, active disease. 15, 16 The corticolimbic system can exhibit a number of alterations, including reduced number of pyramidal neurons in the hippocampus and interneurons in the cingulate cortex, cytoarchitectonic abnormalities in the entorhinal cortex, altered orientation of hippocampal pyramidal cells as well as enlarged ventricles. [9] [10] [11] [16] [17] [18] [19] Some patients also exhibit reduction of interneurons and an increased number of apical dendrites in layer II of the prefrontal cortex. 17 Moreover, disorientation of pre-alpha cells in layer II of the entorhinal cortex suggests a problem with embryonic neuroblast migration and/or differentiation. 11, 20, 21 More detailed pathological information and discussion are available in recent reviews. [22] [23] [24] What could cause such abnormalities during development? Given the genetic component in schizophrenia, mutations could directly cause problems in brain development. Alternatively, mutations could predispose a fetus to higher risk from environmental factors such as infection or anoxia. 1, 25, 26 In this respect, it will be of great interest to see, when the genes that underlie increased risk for schizophrenia are identified, if their functions interact with known environmental factors.
Phenotypic abnormalities in brain neurons
The advent of molecular genetic tools has enabled the quantitation of neural molecules and comparisons between patients and control subjects (Table 1) . Initial studies have focused on various presynaptic and structural molecules in the brain. In general, phenotypic expression of neuronal markers is impaired without apparent sign of neuronal degeneration or gliosis. This is consistent with the possibility of an early developmental problem, but does not provide firm evidence for this notion.
Synaptophysin is one of the membrane proteins localized to synaptic vesicles, and antibodies against it can accurately identify presynaptic sites. Postmortem studies reveal that synaptophysin levels are reduced in the hippocampus 27, 28 and prefrontal cortex 29, 30 of schizophrenic patients. In contrast, its expression is increased in cingulate cortex in schizophrenia. 31 Similarly, other presynaptic proteins important for transmitter release, syntaxin 31 and synapsin, 32 are also affected in schizophrenia. Protein levels for syntaxin are increased in the cingulate cortex while those for synapsin are decreased in the hippocampus of patients. These results could reflect the aberrant synaptic organization or loss of connections that has been suggested from neuropathological studies. 33 In addition, the expression of several structural molecules is altered in schizophrenia; 30, [34] [35] [36] [37] MAP2 and MAP5, which influence dendrite morphology, NCAM, which is involved in neuronal migration and synaptogenesis, and GAP43, Molecular Psychiatry which is thought to contribute to synapse formation and reorganization. Since all these proteins are suggested to contribute to synaptic plasticity of the type found in long-term potentiation (LTP), 38, 39 altered levels could lead to impaired synaptic function and plasticity in schizophrenia.
Early postmortem studies on schizophrenic brain dealt with abnormalities in neurotransmitters and their receptors as analyzed by pharmacological and immunochemical approaches. [40] [41] [42] Recent studies are further exploring such phenotypic abnormalities with molecular techniques (Table 2) . One intriguing finding is an impaired expression of glutamate receptors in the hippocampal areas where various structural/ pathological abnormalities in schizophrenic brain have been observed. [43] [44] [45] [46] Levels of mRNAs for AMPA, kainate and NMDA glutamate receptor subunits are abnormal, and some of these changes have been confirmed at the protein level. 47 Reduction of transmitter receptors is not a generalized phenomenon in schizophrenia, however. In the cingulate and frontal cortex, for instance, GABA-A receptor expression is somewhat elevated in schizophrenia. [48] [49] [50] Some of the findings from schizophrenic brain are controversial, and in some cases treatment of patients with neuroleptic drugs may confound the results.
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Neuronal differentiation and trophic factors in schizophrenia
In considering the altered levels of proteins and mRNAs observed in schizophrenic brains, it is important to ask how these molecules are normally regulated, both during development and in maturity. It is well known that cytokines and growth factors can regulate such gene expression. Among these factors, the neurotrophins have been the most intensively studied. Intriguingly, there is a striking overlap between the molecules regulated by brain-derived neurotrophic factor (BDNF) and those altered in schizophrenia (Table  3) . For instance, reelin, synaptophysin, glutamate receptor subunits GluR1 and GluR2, glutamic acid decarboxylase (GAD67), calbindin D, neuronal nitric oxide synthase (nNOS) and several neuropeptides are specifically regulated in brain neurons by BDNF and/or neurotrophin-3 (NT-3). [52] [53] [54] [55] [56] [57] [58] [59] Although it is unclear whether these neurochemical alterations actually underlie the psychiatric symptoms of this disease, this correlation indicates that further investigation is warranted.
In addition to growth factor regulation of particular phenotypic markers, growth factors also play a role in the development and reorganization of brain circuitry. For instance, infusion of NGF, 60 BDNF or NT-4 61 perturbs the normal formation of ocular dominance columns of the postnatal visual system. Exogenous BDNF and NT-4 also induce marked dendritic arborization in the visual cortex. 62 Moreover, BDNF regulates activitydependent synapse formation and rearrangement in the somatosensory whisker barrel fields. 63 It seems that exogenous neurotrophins act to compensate for the loss of neural activity, thereby maintaining functional synapses and the capacity for plasticity. Thus, neurotrophins are likely to contribute to activity-dependent changes in circuits, probably both at early stages when the cortical plate is developing, and at later stages when cortical circuitry is refined by sensory input from the organism's environment. Thus, schizophrenia could involve an abnormality in an aspect of neurotrophin signaling pathways, which leads to impaired synapse formation and rearrangement. Some abnormalities in schizophrenic brain have been attributed to abnormal migration of interneurons from the cortical subplate. 15, 16, 64 During neocortical development, subplate cells express the neuropeptides somatostatin and neuropeptide Y, and form active synapses that regulate the subsequent formation of cortical layers and thalamocortical circuits. 65 Later in development, most subplate cells undergo apoptosis, disappearing by adulthood. Some subplate cells, however, migrate into the cortical plate, where they become interstitial GABAergic neurons. In schizophrenic brains, the distribution of these interstitial neurons is perturbed, 64 raising the possibility that an abnormality in subplate cell migration or death may be part of the problem in schizophrenia. Consistent with this idea, GAD mRNA and protein levels are decreased significantly in the frontal cortex of schizophrenic patients. 66 These results suggest that the phenotypic abnormalities listed in Tables 1 and 2 may reflect impaired cell migration rather than perturbed gene expression. A mouse mutation that causes a migration defect in the embryonic cortex has implications in this context as well.
The reeler gene mutation causes cortical/hippocampal dysplasia that leads to a dramatic behavioral phenotype, as indicated by the name. 67 The gene product reelin is secreted into the extracellular matrix by Retzius-Cajal cells, and importantly, these cells in the marginal zone express the neurotrophin TrkB receptor and are responsive to BDNF during development. 68 Over-expression of BDNF leads to reduced reelin and cortical malformation. 69 Moreover, impaired expression of reelin was recently detected in schizophrenic brain. 70 Future developmental studies can illuminate connections between neurotrophins and neuronal migration.
Based on this developmental hypothesis, several groups have begun to analyze growth factor and cytokine expression in schizophrenia, and are searching for a possible genetic linkage to this disease. [71] [72] [73] [74] [75] One study found that neurotrophin signaling appears to be impaired in the corticolimbic regions of schizophrenic brains; 76 BDNF levels are specifically elevated in the hippocampus and cingulate cortex, and conversely, its receptor, trkB protein is lower in the prefrontal cortex and hippocampus. Schramm et al 77 further reported a significant decrease in NT-3 receptor (trkC) mRNA in the prefrontal cortex. In contrast, other neurotrophins, NGF and NT-3, fail to exhibit such abnormalities. Although it is uncertain whether perturbations of neurotrophic signaling can be seen before manifestation of the illness, alterations in BDNF levels are evident in serum of young patients (HN, unpublished data). 78 Moreover, the latter observation cannot be mimicked by neuroleptic treatment of rodents, thus indicating a significant link between the neurotrophic abnormality and schizophrenia itself. Similarly altered expression of BDNF is, however, often found in other neuropsychiatric diseases such as epilepsy 79 and depression. 80 Although it is uncertain whether psychotic symptoms of these diseases directly involve such alteration in neurotrophin signaling, the neurotrophic factor BDNF, at least, serves as a good molecular marker reflecting functional conditions of the brain. Thus far, there is no consistent genetic linkage between BDNF, NT-3, or the cytokine ciliary neurotrophic factor in schizophrenia. [81] [82] [83] In contrast, a polymorphism of the cytokine interleukin-1 (IL-1) gene complex appears to be linked to this disease. 84 It is not necessary, however, that growth factor or cytokine genes themselves be mutated to yield the alterations observed in schizophrenic brain, as expression and signaling of these factors can be dynamically altered by many environmental influences, including stress, infection, hormones and brain activity (see below). 85, 86 In addition to their developmental effects, there is growing evidence that cytokines and growth factors are produced by neurons and glia in the adult brain, and that they can acutely influence synaptic transmission. Moreover, these proteins can regulate synaptic plasticity in models of learning and memory. For instance, Molecular Psychiatry studies using exogenous application or antagonist perturbation of many factors have shown alterations in LTP, including BDNF, IL-1␤, transforming growth factor ␤ (TGF␤), epidermal growth factor, fibroblast growth factor, IL-6, interferon (IFN), tumor necrosis factor and IL-2. In addition, the levels of BDNF, IL-1␤, activin ␤A, TGF␤, neuregulin (NDF) and IL-6 are regulated by the induction of LTP. [87] [88] [89] Thus, alterations in the levels of such factors can lead to profound changes in synaptic efficacy, and changes in synaptic function can alter factor levels. In this context it is important to note that stress, trauma, peripheral infection or seizure can also lead to the induction of cytokine expression in both neurons and glia, as well as in immune cells that may infiltrate into the brain, depending on the particular circumstances. 90, 91 Given the effects of cytokines on synaptic transmission and plasticity, it would not be surprising if some of the environmental events just cited could lead to cognitive changes, perhaps similar to those seen in schizophrenia. In fact, systemic application of cytokines in humans can provoke a number of psychiatric symptoms. During the clinical trial of IFN for treatment of viral infection, volunteers exhibited various psychiatric changes. [92] [93] [94] Similarly, a high dose of IL-2 for cancer therapy can provoke schizophrenia-like psychotic Abbreviations: ChAT, choline acetyltransferase; TH, tyrosine hydroxylase; GDNF, glial cell derived neurotrophic factor; CNTF, ciliary neurotrophic factor.
symptoms including delusion and cognitive impairment. 95 Conversely, impaired production and abnormal content of various cytokines are detected in schizophrenic patients (further information can be found in several reviews). 12, 14, 75, 94 These and other studies highlight the potential influence of environmental events, such as peripheral infection, on brain function, with particular focus on brain cytokines. 12, 14, 90, 96 Interaction between cytokines and neuronal differentiation factors in the brain As cited above, epidemiological studies have indicated that environmental factors such as the season of birth and prenatal viral infection are significant risk factors for schizophrenia. Such findings bring together the developmental and immune hypotheses of this disease. Moreover, growth factors and cytokines can provide a molecular basis for this interaction, as these factors are well known to cross-regulate each other (Table 4 ). It is noteworthy that the inflammatory cytokines, IL-1␤ and TGF␣ can suppress normal expression of BDNF, one of the key neuronal developmental regulators, as discussed above. 97, 98 On the other hand, IL-1␤ can upregulate expression of NGF. 99, 100 Maternal viral infection is one of the ways that cytokines could perturb brain development. In agreement with these ideas, Fatemi et al 101 have shown that maternal infection with human influenza virus alters expression of reelin in the developing mouse brain, a protein that is associated with abnormal cortical layer formation, as discussed above. It will be of great interest to determine which cytokines and growth factors maternal viral infection perturbs, both in the mother and the fetus. This animal model is important because it is based on epidemiological findings, rather than on injury or drug treatment.
Perspectives
Previous neurochemical studies implicated dopaminergic and glutamatergic neurotransmitter systems in schizophrenic pharmacology. 102, 103 Consistent with this view, various neurotrophic factors including BDNF are known to influence dopamine synthesis as well as glutamatergic neurotransmission. [104] [105] [106] [107] In addition, it is now clear that neurotransmitters such as dopamine, serotonin, GABA, excitatory amino acids and various neuropeptides and their receptors are altered in the schizophrenic brain. Such transmitters and neuropeptides are known to function during development, where they can regulate neuronal survival, differentiation and maturation, [108] [109] [110] as well as synaptic plasticity. 111, 112 Taken together, we suggest that these data support a model in which cognitive and emotional impairments of schizophrenic patients are caused by two fundamental alterations; persistent qualitative (structural/phenotypic) neural changes that occurred during development, and impaired synaptic plasticity caused by quantitative and qualitative changes in (Figure 1 ). Genetic background provides a substrate for intrinsic maldevelopment of the brain and environmental influences recruit neurotrophic factors and cytokines to trigger the changes that lead to impaired neural functions. This model helps explain the sporadic manifestation of the illness as well as its relatively late emerg- Figure 1 The neurodevelopmental hypothesis for schizophrenia etiology; combinatorial and cumulative influences of genetic background and environmental influences leading to brain maldevelopment through altered neurotrophic factors and cytokines. Disastrous brain dysfunction is ultimately manifested after adolescence when brain development is completed. Abbreviations used; IFN, interferon; IL, interleukin; AMPA-R, AMPA-type glutamate receptors; NMDA-R, NMDA-type glutamate receptors.
Molecular Psychiatry ence, after adolescence. Both genetic and molecular pathological studies are essential to prove such a hypothesis. It is also critical to develop new animal models, such as the viral model previously mentioned. In addition, there are the problems of the biological definition of, and biomarkers for, schizophrenia. Perhaps future work will solidify the use of brain imaging and the identification of proteins such as cytokines in the classification of patients.
